Gastroenterologists continue to feel the resonating effects of the COVID-19 pandemic as they work to return operations to pre-pandemic levels,...
Though surveyed US specialists report shrinking trepidation prescribing certain drugs amid the COVID-19 pandemic, hesitation to prescribe new brands remains...
According to Spherix Global Insights, just one-tenth of specialty physician offices are operating at normal capacity, and doctors report facing...
According to feedback from the sixth wave of COVID-19 impact tracking, Spherix Global Insights finds that patient volumes remain severely...
Use in treatment-naïve patients drives recent growth of Biogen’s Tecfidera and Genzyme’s Aubagio in Canada, as reported switch share has...
EXTON, Pa., April 20, 2020 /PRNewswire/ ― Spherix Global Insights, the leading independent market intelligence firm in specialty biopharma markets,...
The impact to practices has been severely disruptive, taking a devastating personal and financial toll on specialty physicians according to...
From: FiercePharma By: Angus Liu COVID-19 is Bad News for New Drug Launches. Which Will Suffer Most? A recent survey...
Looking to the future, the approval of the first dual-therapy migraine label would make Nurtec a substantial competitive threat on...
Results from a survey of more than 300 dermatologists, gastroenterologists, nephrologists, neurologists, rheumatologists, and primary care physicians indicate a marked...
